References
- Biron K.K.: Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154–163 (2006)
- Bocian J., Januszkiewicz-Lewandowska D.: HCMV infections after hematopoietic stem cell transplantation – diagnostic methods and importance of viral DNA level monitoring. Post. Hig. Med. Dosw. 69, 252–263 (2015)
- Bright P.D., Gompels M., Donati M., Johnston S.: Successful oral treatment of ganciclovir resistant cytomegalovirus with maribavir in the context of primary immunodeficiency: First case report and review. J. Clin. Virol. 87, 12–16 (2017)
- Britt W.J., Prichard M.N.: New therapies for human cytomegalovirus infections. Antiviral Res. 159, 153–174 (2018)
- Chaer F.E., Shah D.P., Chemaly R.F.: How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 128, 2624–2636 (2016)
- Chemaly RF, Hill J., Voigt S., Peggsd K.S.: In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Res. 163, 50–58 (2019)
- Chen H., Li C., Zemlicka J., Gentry B.G., Bowlin T.L., Coena D.M.: Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA Polymerase. Antimicrob. Agents Chemother. 60, 4176–4182 (2016)
- Chou S.: Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. Antiviral Res. 138, 57–60 (2017)
- Chou S., Ercolani R.J., Derakhchan. K.: Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Res. 157, 128–133 (2018)
- Czarnecka P., Czarnecka K., Tronina O., Durlik M.: Cytomegalovirus disease after liver transplant-a description of a treatment-resistant case: a case report and literature review. Transplant Proc. 50, 4015–4020 (2018)
- Dadwal S.S.: Update on prevention of cytomegalovirus in hematopoietic cell transplantation. Curr. Opin. Infect. Dis. 32, 63–68 (2019)
- Dęborska-Materkowska D., Durlik M.: Leczenie zakażenia wirusem cytomegalii po transplantacji nerki. Forum Nefrologiczne 3, 162–168 (2010)
- Durlik M.: Cytomegalovirus infection in transplant recipients. Nefrol. Dial. Pol. 13, 157–163 (2009)
- Dzieciątkowski T., Rola A., Majewska A., Solarska M., Łuczak M.: Leki stosowane w leczeniu zakażeń herpeswirusami u ludzi. Post. Mikrobiol. 46, 211–221 (2007)
- Foster S.A., Parker S., Lanier R.: The role of brincidofovir in preparation for a potential smallpox outbreak. Viruses 9, 320 (2017)
- Frange P., Leruez-Ville M.: Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med. Mal. Infect. 48, 495–502 (2018)
- Gentry B.G., Drach J.C.: Metabolism of cyclopropavir and ganciclovir in Human Cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 58, 2329–2333 (2014)
- Jackson J.W., Hancock T.J., Dogra P., Patel R., Arav-Boger R., Williams A.D., Kennel S.J., Wall J.S., Sparer T.E.: Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screenings. mSphere, 13, e00586–18 (2019)
- Koval C.E.: Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Infect. Dis. Clin. North Am. 32, 581–559 (2018)
- Leś, nikowski Z.J., Paradowska E., Przepiórkiewicz M., Bogusława-Olejniczak A., Emery V.: Leki przeciwko ludzkiemu wirusowi cytomegalii (hCMV). Pol. Merkur. Lek. XIII, 242–249 (2002)
- Ligat G., Cazal R., Hantz S., Alain S.: The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol. Rev. 42, 137–145 (2018)
- Majewska A., Młynarczyk-Bonikowska B., Malejczyk M., Majewski S., Młynarczyk G.: Antiviral medication in sexually transmitted diseases. Part III: Hepatitis B, Hepatitis C. Mini Rev. Med. Chem. 17, 328–337 (2017)
- Majewska A., Młynarczyk-Bonikowska B., Malejczyk M., Młynarczyk G., Majewski S.: Antiviral medication in sexually transmitted diseases. Part II: HIV. Mini Rev. Med. Chem. 15, 93–103 (2015)
- Marty F.M., Badshah C. i wsp.: Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl. J. Med. 377, 2433–2444 (2017)
- McIntosh M., Hauschild B., Miller V.: Human cytomegalovirus and transplantation: drug development and regulatory issues. J. Virus Erad. 2, 143–148 (2016)
- Mizuguchi T., Ohashi N., Matsumoto D., Hashimoto C., Nomura W., Yamamoto N., Murakami T., Tamamura H.: Development of anti-HIV peptides based on a viral capsid protein. Biopolymers, 108, DOI: 10.1002/bip.22920 (2017)
- Młynarczyk-Bonikowska B, Majewska A., Malejczyk M., Młynarczyk G., Majewski S.: Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. Mini Rev. Med. Chem. 3, 1837–1845 (2013)
- Ndeboko B., Hantz O., Lemamy G.J., Cova L.: Developments in cell-penetrating peptides as antiviral agents and as vehicles for delivery of peptide nucleic acid targeting hepadnaviral replication pathway. Biomolecules, 8, DOI: 10.3390/biom8030055 (2018)
- O’, Brien M.S., Markovich K.C., Selleseth D., DeVita A.V., Sethna P., Gentry B.G.: In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antiviral Res. 158, 255–263 (2018)
- Piret J., Boivin G.: Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 163, 91–105 (2019)
- Pokorska-Śpiewak M., Niezgoda A., Gołkowska M., Czech-Kowalska J., Gruszfeld D., Dobrzańska A., Styczyński J., Marczyńska M.: Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przegl. Epidemiol. 70, 297–310 (2016)
- Poole C.L., James S.H.: Antiviral therapies for Herpesviruses: current agents and new directions. Clin. Ther. 40, 1282–1298 (2018)
- Razonable R.R.: Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 86, 1009–1026 (2011)
- Razonable R.R.: Drug-resistant cytomegalovirus: clinical implications of specific mutations. Curr. Opin. Organ Transplant. 23, 388–394 (2018)
- Styczynski J.: Who is the patient at risk of CMV recurrence: A review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect. Dis. Ther. 7, 1–16 (2017)
- Tan B.H.: Cytomegalovirus treatment. Curr Treat Options Infect Dis. 6, 256–270 (2014)
- Tippin T.K., Morrison M.E., Brundage T.M., Momméja-Marin H. : Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther. Drug. Monit. 38, 777–786 (2016)
- Tylden G.D., Hirsch H.H., Rinaldo C.H.: Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Antimicrob. Agents Chemother. 59, 3306–3316 (2015)
- Wong D.D., van , Zuylen W.J., Craig M.E., Rawlinson W.D.: Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients. Rev. Med. Virol. 29, e2023, DOI: 10.1002/rmv.2023 (2019)
- Wu Z., Drach J.C., Prichard M.N., Yanachkova M., Yanachkov I., Bowlin T.L., Zemlicka J.: L-valine ester of cyclopropavir: a new antiviral prodrug. Antivir. Chem. Chemother. 20, 37–46 (2009)
- Zhao H., Zheng B.J. i wsp.: A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci. Rep. 6, DOI: 10.1038/srep22008 (2016)